All In Biotech

NDA 021986 · Bristol Myers Squibb

Sprycel

Dasatinib · Oral

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Jun 28, 2006

Approved uses

10

Original approval plus efficacy supplements

Registered trials

366

28 Phase 3, 24 recruiting

FAERS reports

37,260

22,458 serious, 3,748 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 16, 2026.

SPRYCEL (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. SPRYCEL is a kinase inhibitor indicated for the treatment of • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. (1 , 14) • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. (1 , 14) • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1 , 14) • pediatric patients 1 year of age and older with Ph+ CML in chronic phase. (1 , 14) • pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy. (1 , 14)

Mechanism: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro , dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • SPRYCEL · DASATINIB 80MG · TABLET, ORAL · Prescription · TE AB
  • SPRYCEL · DASATINIB 70MG · TABLET, ORAL · Prescription · TE AB
  • SPRYCEL · DASATINIB 20MG · TABLET, ORAL · Prescription · TE AB
  • SPRYCEL · DASATINIB 140MG · TABLET, ORAL · Prescription · TE AB
  • SPRYCEL · DASATINIB 100MG · TABLET, ORAL · Prescription · TE AB
  • SPRYCEL · DASATINIB 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dasatinib" as an intervention, any sponsor and status, largest first.

All 366 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pleural effusion3,282
  • fatigue2,554
  • diarrhoea2,178
  • nausea2,151
  • death2,131
  • headache2,014
  • rash1,618
  • drug ineffective1,554
  • dyspnoea1,513
  • adverse event1,478
  • off label use1,321
  • hospitalisation1,223

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200694
2007313
2008417
2009406
2010519
2011522
20121,181
20131,281
20142,403
20152,571
20162,506
20172,408
20182,703
20193,279
20202,830
20212,942
20222,643
20232,739
20242,897
20251,632
2026974

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sprycel (Dasatinib)

2024 spending

$518M

Beneficiaries

5,393

38,789 claims

Per beneficiary

$96,112

$438.00 per unit

View as table
YearSpending
2020$418,689,356
2021$450,220,328
2022$500,484,016
2023$510,233,995
2024$518,330,507

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 351 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.